Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
4,315,299
-
Shares change
-
-4,512,690
-
Total reported value, excl. options
-
$8,240,101
-
Value change
-
-$19,328,651
-
Put/Call ratio
-
81.49%
-
Number of buys
-
19
-
Number of sells
-
-19
-
Price
-
$1.91
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2021
53 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q2 2021.
Protalix BioTherapeutics, Inc. - COM (PLX) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4,315,299 shares
.
Largest 10 shareholders include MORGAN STANLEY (1,861,769 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (393,890 shares), Walleye Capital LLC (346,539 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (283,145 shares), MEITAV DASH INVESTMENTS LTD (244,332 shares), Phoenix Holdings Ltd. (244,113 shares), GROUP ONE TRADING, L.P. (179,088 shares), Walleye Trading LLC (135,000 shares), BlackRock Inc. (122,499 shares), and CITADEL ADVISORS LLC (115,886 shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.